|
1 |
|
Series 2 Episode 8 - Navigating a genetic diagnosis |
What might it be like to navigate a genetic diagnosis and share it with family members? We talk to Julie Young from the CanGene CanVar patient reference panel about her experience. |
Rachel Horton, Gabrielle Samuel, Julie Young |
12 Jun 2023 |
|
2 |
|
Series 2 Episode 6 - Diversifying genomics |
What are the ethical challenges with diversifying genomic data? We talk to Faranak Hardcastle about her work exploring this. |
Rachel Horton, Gabrielle Samuel, Faranak Hardcastle |
07 Mar 2023 |
|
3 |
|
Series 2 Episode 5 - Who's 'the patient' in genomic medicine? |
We live our lives alongside others, and our decisions have consequences for those close to us - what does this mean for how we define 'the patient' in genomic medicine? Susie Weller talks to us about this issue. |
Rachel Horton, Gabrielle Samuel, Susie Weller |
25 Jan 2023 |
|
4 |
Creative Commons |
Series 2 Episode 2 - Why context matters in genetic testing |
How can the same genetic finding can mean different things in different people? What does this mean for 'personalising' genetic results? Anneke Lucassen talks to us about this issue. |
Rachel Horton, Gabrielle Samuel, Anneke Lucassen |
18 Jul 2022 |
|
5 |
|
Series 2 Episode 1 - The environmental cost of personalised medicine |
How does personalised medicine impact on the environment? What does this mean for how we should collect and store data? Gabrielle Samuel talks to us about these issues. |
Rachel Horton, Gabrielle Samuel, Susie Weller |
16 Jun 2022 |
|
6 |
|
Series 1 Episode 2 - Meet the Advisory Board: Dame Mary Archer |
In the second episode of the Meet the Advisory Board Series we talked to Dame Mary Archer about personalised medicine in practice, her academic career and her plethora of other roles she has held and is holding at the moment. |
Anika Knuppel, Jiyoon Lee, Dame Mary Archer |
25 Jun 2021 |
|
7 |
|
Equity and commissioning - Richard Sullivan |
Session 4: Equity and commissioning - Richard Sullivan |
Mark Sheehan, Richard Sullivan |
19 Jan 2017 |
|
8 |
|
Equity and commissioning - Muir Gray |
Session 4: Equity and commissioning - Muir Gray |
Muir Gray, Mark Sheehan |
19 Jan 2017 |
|
9 |
|
Data sharing and participation - Jonathan Montgomery |
Session 3: Data sharing and participation - Jonathan Montgomery |
Ingrid Slade, Jonathan Montgomery |
19 Jan 2017 |
|
10 |
|
Data sharing and participation - Anna Middleton |
Session 3: Data sharing and participation - Anna Middleton |
Ingrid Slade, Anna Middleton |
19 Jan 2017 |
|
11 |
|
Data sharing and participation - Mark Lawler |
Session 3: Data sharing and participation - Mark Lawler |
Mark Lawler, Ingrid Slade |
19 Jan 2017 |
|
12 |
|
The human person and the communication of risk - Sian Rees |
Session 2: The human person and the communication of risk - Sian Rees |
Rob Horne, Sian Rees |
19 Jan 2017 |
|
13 |
|
The human person and the communication of risk - Alastair Kent |
Session 2: The human person and the communication of risk - Alastair Kent |
Rob Horne, Alastair Kent |
19 Jan 2017 |
|
14 |
|
The human person and the communication of risk - Joshua Hordern |
Session 2: The human person and the communication of risk - Joshua Hordern |
Joshua Hordern, Rob Horne |
19 Jan 2017 |
|
15 |
|
The promise and the hype of 'personalised medicine' - John Tooke |
Session 1: The promise and the hype of 'personalised medicine' - John Tooke |
Joshua Hordern, John Tooke |
19 Jan 2017 |
|
16 |
|
The promise and the hype of 'personalised medicine' - Steve Sturdy |
Session 1: The promise and the hype of 'personalised medicine' - Steve Sturdy |
Steve Sturdy, Joshua Horden |
19 Jan 2017 |
|
17 |
|
The promise and the hype of 'personalised medicine' - Tim Maughan |
Session 1: The promise and the hype of 'personalised medicine' - Tim Maughan |
Tim Maughan, Joshua Hordern |
19 Jan 2017 |
|
18 |
|
Highlights of Personalised Medicine |
Highlights of Personalised Medicine: the promise, the hype and the pitfalls |
Alastair Kent, Anna Middleton, Marion Lynch, Muir Gray |
19 Jan 2017 |
|
19 |
|
Personalised Medicine, interview with Jonathan Montgomery |
Personalised Medicine: the promise, the hype and the pitfalls, a short interview with Jonathan Montgomery |
Jonathan Montgomery |
18 Jan 2017 |
|
20 |
|
Personalised Medicine, interview with Anna Middleton |
Personalised Medicine: the promise, the hype and the pitfalls, a short interview with Anna Middleton |
Anna Middleton |
18 Jan 2017 |
|
21 |
|
Personalised Medicine, interview with Marion Lynch |
Personalised Medicine: the promise, the hype and the pitfalls, a short interview with Marion Lynch |
Marion Lynch |
18 Jan 2017 |
|
22 |
|
Personalised Medicine, interview with Mark Lawler |
Personalised Medicine: the promise, the hype and the pitfalls, a short interview with Mark Lawler |
Mark Lawler |
18 Jan 2017 |
|
23 |
|
Personalised Medicine, interview with Alastair Kent |
Personalised Medicine: the promise, the hype and the pitfalls, a short interview with Alastair Kent |
Alastair Kent |
18 Jan 2017 |
|
24 |
|
Personalised Medicine, interview with Rick Kaplan |
Personalised Medicine: the promise, the hype and the pitfalls, a short interview with Rick Kaplan |
Rick Kaplan |
18 Jan 2017 |
|
25 |
|
Personalised Medicine, interview with Muir Gray |
Personalised Medicine: the promise, the hype and the pitfalls, a short interview with Muir Gray |
Muir Gray |
18 Jan 2017 |
|
26 |
|
How can massive genetic studies help us prevent and treat diabetes? |
Any pair of individuals will share 99.9% of their DNA. But that 0.1% difference can tell us a huge amount about the causes of disease and how we can treat them. Find out more about the genetics that underpin type 2 diabetes. |
Mark McCarthy |
11 Jul 2016 |
|
27 |
Creative Commons |
Repairing DNA damage |
Dr Ross Chapman studies the molecular events triggered by DNA damage detection, and why defects in these events lead to immune deficiency and cancer in humans. |
Ross Chapman |
28 Apr 2016 |
|
28 |
Creative Commons |
Repairing DNA damage |
Dr Ross Chapman studies the molecular events triggered by DNA damage detection, and why defects in these events lead to immune deficiency and cancer in humans. |
Ross Chapman |
28 Apr 2016 |
|
29 |
|
'Explosions' part 3 - Health and Big Data |
Professor Gil McVean explains what Big Data is and how it can be used to better understand and treat complex conditions, such as heart disease and dementia. |
Gil McVean |
30 Mar 2015 |
